Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option
Results reinforce the well-established safety profile of Dupixent - the first-ever biologic medicine for atopic dermatitis currently approved for patients as young 6 years old
Brian Foard will lead the Specialty Care GBU ad interim, effective immediately.
Bayer reported the highest market capitalization growth of 23.1% during Q1 2023
Viehbacher brings extensive international experience in large pharmaceutical and entrepreneurial biotech companies
Futnani has over two decades of experience in delivering growth and transformation that spans several therapeutic areas.
Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
Twelve abstracts and two late-breaking presentations demonstrate AbbVie and Allergan Aesthetics' shared commitment to advancing research across a spectrum of dermatologic conditions and aesthetic indications
Subscribe To Our Newsletter & Stay Updated
